Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator-activated receptor γ

Raphael Nemenoff, Amy M. Meyer, Tyler M. Hudish, Anthony B. Mozer, Amy Snee, Shuh Narumiya, Robert Stearman, Robert A. Winn, Mary Weiser-Evans, Mark W. Geraci, Robert L. Keith

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Overexpression of prostacyclin synthase (PGIS) decreases lung tumor multiplicity in chemical- and cigarette-smoke-induced murine lung cancer models. Prostacyclin signals through a single G-protein-coupled receptor (IP), which signals through cyclic AMP. To determine the role of this receptor in lung cancer chemoprevention by prostacyclin, PGIS-overexpressing mice were crossed to mice that lack the IP receptor [IP(-/-)]. Carcinogen-induced lung tumor incidence was similar in IP(+/+), IP(+/-), and IP(-/-) mice, and overexpression of PGIS gave equal protection in all three groups, indicating that the protective effects of prostacyclin are not mediated through activation of IP. Because prostacyclin can activate members of the peroxisomal proliferator-activated receptor (PPAR) family of nuclear receptors, we examined the role of PPARγ in the protection of prostacyclin against lung tumorigenesis. Iloprost, a stable prostacyclin analogue, activated PPARγ in nontransformed bronchial epithelial cells and in a subset of human non-small-cell lung cancer cell lines. Iloprost-impregnated chow fed to wild-type mice resulted in elevated lung macrophages and decreased lung tumor formation. Transgenic animals with lung-specific PPARγ overexpression also developed fewer lung tumors. This reduction was not enhanced by administration of supplemental iloprost. These studies indicate that PPARγ is a critical target for prostacyclin-mediated lung cancer chemoprevention and may also have therapeutic activity.

Original languageEnglish (US)
Pages (from-to)349-356
Number of pages8
JournalCancer Prevention Research
Volume1
Issue number5
DOIs
StatePublished - Oct 2008
Externally publishedYes

Fingerprint

Epoprostenol
Lung Neoplasms
Lung
Membranes
Iloprost
Chemoprevention
Neoplasms
Civil Rights
Genetically Modified Animals
Cytoplasmic and Nuclear Receptors
G-Protein-Coupled Receptors
Non-Small Cell Lung Carcinoma
Smoke
Tobacco Products
Carcinogens
Cyclic AMP
Carcinogenesis
Epithelial Cells
Macrophages
Cell Line

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator-activated receptor γ. / Nemenoff, Raphael; Meyer, Amy M.; Hudish, Tyler M.; Mozer, Anthony B.; Snee, Amy; Narumiya, Shuh; Stearman, Robert; Winn, Robert A.; Weiser-Evans, Mary; Geraci, Mark W.; Keith, Robert L.

In: Cancer Prevention Research, Vol. 1, No. 5, 10.2008, p. 349-356.

Research output: Contribution to journalArticle

Nemenoff, R, Meyer, AM, Hudish, TM, Mozer, AB, Snee, A, Narumiya, S, Stearman, R, Winn, RA, Weiser-Evans, M, Geraci, MW & Keith, RL 2008, 'Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator-activated receptor γ', Cancer Prevention Research, vol. 1, no. 5, pp. 349-356. https://doi.org/10.1158/1940-6207.CAPR-08-0145
Nemenoff, Raphael ; Meyer, Amy M. ; Hudish, Tyler M. ; Mozer, Anthony B. ; Snee, Amy ; Narumiya, Shuh ; Stearman, Robert ; Winn, Robert A. ; Weiser-Evans, Mary ; Geraci, Mark W. ; Keith, Robert L. / Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator-activated receptor γ. In: Cancer Prevention Research. 2008 ; Vol. 1, No. 5. pp. 349-356.
@article{64ebbe90db804101be7fe40ec19b9f80,
title = "Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator-activated receptor γ",
abstract = "Overexpression of prostacyclin synthase (PGIS) decreases lung tumor multiplicity in chemical- and cigarette-smoke-induced murine lung cancer models. Prostacyclin signals through a single G-protein-coupled receptor (IP), which signals through cyclic AMP. To determine the role of this receptor in lung cancer chemoprevention by prostacyclin, PGIS-overexpressing mice were crossed to mice that lack the IP receptor [IP(-/-)]. Carcinogen-induced lung tumor incidence was similar in IP(+/+), IP(+/-), and IP(-/-) mice, and overexpression of PGIS gave equal protection in all three groups, indicating that the protective effects of prostacyclin are not mediated through activation of IP. Because prostacyclin can activate members of the peroxisomal proliferator-activated receptor (PPAR) family of nuclear receptors, we examined the role of PPARγ in the protection of prostacyclin against lung tumorigenesis. Iloprost, a stable prostacyclin analogue, activated PPARγ in nontransformed bronchial epithelial cells and in a subset of human non-small-cell lung cancer cell lines. Iloprost-impregnated chow fed to wild-type mice resulted in elevated lung macrophages and decreased lung tumor formation. Transgenic animals with lung-specific PPARγ overexpression also developed fewer lung tumors. This reduction was not enhanced by administration of supplemental iloprost. These studies indicate that PPARγ is a critical target for prostacyclin-mediated lung cancer chemoprevention and may also have therapeutic activity.",
author = "Raphael Nemenoff and Meyer, {Amy M.} and Hudish, {Tyler M.} and Mozer, {Anthony B.} and Amy Snee and Shuh Narumiya and Robert Stearman and Winn, {Robert A.} and Mary Weiser-Evans and Geraci, {Mark W.} and Keith, {Robert L.}",
year = "2008",
month = "10",
doi = "10.1158/1940-6207.CAPR-08-0145",
language = "English (US)",
volume = "1",
pages = "349--356",
journal = "Cancer Prevention Research",
issn = "1940-6207",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator-activated receptor γ

AU - Nemenoff, Raphael

AU - Meyer, Amy M.

AU - Hudish, Tyler M.

AU - Mozer, Anthony B.

AU - Snee, Amy

AU - Narumiya, Shuh

AU - Stearman, Robert

AU - Winn, Robert A.

AU - Weiser-Evans, Mary

AU - Geraci, Mark W.

AU - Keith, Robert L.

PY - 2008/10

Y1 - 2008/10

N2 - Overexpression of prostacyclin synthase (PGIS) decreases lung tumor multiplicity in chemical- and cigarette-smoke-induced murine lung cancer models. Prostacyclin signals through a single G-protein-coupled receptor (IP), which signals through cyclic AMP. To determine the role of this receptor in lung cancer chemoprevention by prostacyclin, PGIS-overexpressing mice were crossed to mice that lack the IP receptor [IP(-/-)]. Carcinogen-induced lung tumor incidence was similar in IP(+/+), IP(+/-), and IP(-/-) mice, and overexpression of PGIS gave equal protection in all three groups, indicating that the protective effects of prostacyclin are not mediated through activation of IP. Because prostacyclin can activate members of the peroxisomal proliferator-activated receptor (PPAR) family of nuclear receptors, we examined the role of PPARγ in the protection of prostacyclin against lung tumorigenesis. Iloprost, a stable prostacyclin analogue, activated PPARγ in nontransformed bronchial epithelial cells and in a subset of human non-small-cell lung cancer cell lines. Iloprost-impregnated chow fed to wild-type mice resulted in elevated lung macrophages and decreased lung tumor formation. Transgenic animals with lung-specific PPARγ overexpression also developed fewer lung tumors. This reduction was not enhanced by administration of supplemental iloprost. These studies indicate that PPARγ is a critical target for prostacyclin-mediated lung cancer chemoprevention and may also have therapeutic activity.

AB - Overexpression of prostacyclin synthase (PGIS) decreases lung tumor multiplicity in chemical- and cigarette-smoke-induced murine lung cancer models. Prostacyclin signals through a single G-protein-coupled receptor (IP), which signals through cyclic AMP. To determine the role of this receptor in lung cancer chemoprevention by prostacyclin, PGIS-overexpressing mice were crossed to mice that lack the IP receptor [IP(-/-)]. Carcinogen-induced lung tumor incidence was similar in IP(+/+), IP(+/-), and IP(-/-) mice, and overexpression of PGIS gave equal protection in all three groups, indicating that the protective effects of prostacyclin are not mediated through activation of IP. Because prostacyclin can activate members of the peroxisomal proliferator-activated receptor (PPAR) family of nuclear receptors, we examined the role of PPARγ in the protection of prostacyclin against lung tumorigenesis. Iloprost, a stable prostacyclin analogue, activated PPARγ in nontransformed bronchial epithelial cells and in a subset of human non-small-cell lung cancer cell lines. Iloprost-impregnated chow fed to wild-type mice resulted in elevated lung macrophages and decreased lung tumor formation. Transgenic animals with lung-specific PPARγ overexpression also developed fewer lung tumors. This reduction was not enhanced by administration of supplemental iloprost. These studies indicate that PPARγ is a critical target for prostacyclin-mediated lung cancer chemoprevention and may also have therapeutic activity.

UR - http://www.scopus.com/inward/record.url?scp=57249089708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57249089708&partnerID=8YFLogxK

U2 - 10.1158/1940-6207.CAPR-08-0145

DO - 10.1158/1940-6207.CAPR-08-0145

M3 - Article

C2 - 19138979

AN - SCOPUS:57249089708

VL - 1

SP - 349

EP - 356

JO - Cancer Prevention Research

JF - Cancer Prevention Research

SN - 1940-6207

IS - 5

ER -